Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
COMMENTARY
Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not everyone in pharma quite knows what to make of it yet. In April, Marubeni announced it would acquire Sumitomo Pharma’s…
To read the full story
Related Article
- Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year
November 25, 2025
- Mochida and Itochu to Each Take 20% Stake in And Pharma
September 24, 2025
- Itochu Launches J-STEP to Help Overseas Drug Makers Tackle Japan’s “Drug Loss”
August 21, 2025
- Marubeni Sees Drug Biz Opportunities in Global Markets with Supply-Demand Gaps
April 16, 2025
- Sumitomo Pharma to Offload Asian Biz to Trader Marubeni
April 2, 2025
- Marubeni Invests in Healthcare Product Distributor in Africa
January 29, 2025
COMMENTARY
- Challenges in a Post-AG Era: Ensuring a Reliable Supply System
April 6, 2026
- Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
April 1, 2026
- A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste
March 24, 2026
- Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches
March 11, 2026
- Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause
March 10, 2026
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…